Fig 1 Adverse events after intravitreal injections of vascular endothelial growth factor inhibitors. *Matched on age, sex, history of outcome, and diabetes. †Matched on age, sex, history of outcome, and diabetes; adjusted for: ischaemic stroke—angiotensin converting enzyme (ACE) inhibitors, acetylsalicylic acid/dipyridamole, cancer in previous 5 years, clopidogrel, hypertension, chronic renal insufficiency, warfarin; acute myocardial infarction—digoxin, ACE inhibitors, cancer in previous 5 years, clopidogrel, diuretics (regular), hypertension, No of unique prescriptions, chronic renal insufficiency, 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors, warfarin; venous thromboembolism—digoxin, glaucoma therapies, ACE inhibitors, cancer in previous 5 years, diuretics (potassium sparing), diuretics (regular), low molecular weight heparin, No of unique prescriptions, 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors, warfarin; congestive heart failure—digoxin, glaucoma therapies, ACE inhibitors, calcium channel blockers, cancer in previous 5 years, clopidogrel, diuretics (potassium sparing), diuretics (regular), hypertension, chronic renal insufficiency, warfarin